Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs#day_2
FYI SUMM presenting
$25m subscription completed..........
Two cases of resistant gonorrhoea diagnosed in the UK
https://www.gov.uk/government/news/two-cases-of-resistant-gonorrhoea-diagnosed-in-the-uk
Your prediction seems to have proved correct, so far. stew200
Thank you Christrdg.
Nice explanation.
Hopefully the price will stay up, because of the extra volume. Even though it wont be on sale, it has a 25p value.
Hi Albino - The shares in question relate to last weeks motions being passed relating to the new investor who has bought a new issue of shares for 25p representing approx 50% of the original SC.These shares will not at this stage be going on to the market as they are the investors own investment in Summit.The SP move this morning reflects the increase on the NASDAQ last night up to $1.85 - £0.29p.I am now showing as a 'Strong Buy'.
Well what ever it means, the Market seems to like it.
I may be reading this wrong, but it looks like a load of new shares tomorrow and the price has gone up today.
This should be flying tomorrow
I like to think of it as someone's New Years Resolution.
Since we've been sat at twenty or below for five weeks.
Without news assume it is just volatility with some pumping and dumping at work.
Time to shoot part mid 20s it would seem
Thanks for the response, Christrdg.
Just a passing interest, the amount I hold makes no difference to anyone.
Hi Albino - With regards the SP the shares will not be going onto the market so SP should not be effected however your share of the company will have halved as has mine.SP should move up when they announce starting Phase 3 C-Diff trials.
Does that mean we will have a price drop, due to extra shares diluting.
Some positivity here today. Let’s hope for a better 12 months than the last. I think that as this price we are undervalued and we should see a much better SP soon. Long term lots and lots of potential but some risks attached. ‘He Who Dares’
Thank you Chris
Hi PharmaGiles - You can go online & will require some details from your share certificate to vote today see link below regards.
https://www.signalshares.com
I won’t be going to the meeting on the 4th but certainly supportive of the additional funding. My feeling is the $25m + BARDA funding should be enough to see these P3 studies through now and really no idea why SUMM are suggesting that this new funding will only extend the cash runway by 4 months. The cost of a clinical trial is driven by 1) the study duration, or more importantly the number of study visits 2) the number/type of procedures undertaken at each visit and 3) the number of patients to be enrolled. Data management costs are also driven by these 3 factors. With regards point 1 - here we’re looking at standard/basic study screening with only a 10 day treatment period, and a handful of study follow up visits (D40, D70 and D100 – maybe some in between?). For point 2 there are no expensive investigations (e.g. MRE, endoscopy, biopsy etc) – just plain and simple clinical assessments, labs, and standard C’diff toxin testing. Point 3 – 1400 pts for a phase III program is not a large # and especially given the straightforward nature of the study design.
I wonder whether SUMM are taking a Big Pharma approach to a small pharma budget? If so they may consider having more team members with small pharma experience in running studies. It’s a very different mind-set, more hands on, more virtual and often means working with small to medium sized CRO’s. You can get from A to B without using a Rolls Royce. Maybe the CFO was pulling his hair out - once he had none left decided to leave?
Chris have you managed to find a way to vote without attending? I’ve not received anything from SUMM (despite emailing), and hold quite a few shares here now.. thank you in advance
North Korea's leader Kim Jong-un has vowed to "frequently" meet South Korea's President Moon Jae-in next year to discuss denuclearisation. In a rare letter to Seoul, Mr Kim said he wished to pursue peace between the countries and "solve the issue of denuclearising the peninsula together", a spokesman for Mr Moon said. Mr Kim also expressed "much regret" that he could not visit Seoul in 2018. He promised to make the trip after Mr Moon visited Pyongyang in September. On his visit to North Korea's capital, Mr Moon gave a speech at the Mass Games, saying the two countries should "become one" again. Although both countries technically remain at war, relations improved markedly in 2018 thanks to a number of conciliatory gestures from Mr Kim. ■ Korean soldiers cross border in peace ■ South Korea unveils Kim Jong-un's puppies ■ Seeing through Kim Jong-un's K-pop sign Mr Moon's spokesman did not reveal how the letter was delivered, but described it as warm and said Mr Kim wrote of his "strong determination to visit Seoul while watching the future situation". Kim Jong-un also met US President Donald Trump in 2018 - the first time a sitting US president has met a leader from the country - but efforts to improve relations between the US and the north have stalled in recent months. The US has said North Korea has not fully committed to giving up its nuclear weapons, while the North has lashed out at fresh US sanctions crippling its economy and targeting members of its government. Despite these setbacks, another summit between Mr Trump and Mr Kim could happen in 2019. The US president praised a "warm letter" from Pyongyang in September, although no date has been set for another meeting.
Let’s hope we finish mid 20s Wednesday
Is anyone going on the 4th January for the Summit shareholders meeting in London - I will be supporting the motions but will not be going.I see it as just a legal necessity & the motions will get passed. I only had wished that they had delayed to after the launch of C-Diff phase 3 for fund raising & maybe been able to negotiate a higher price than 25p.Hey Ho.